The Ohio State University Comprehensive Cancer Center (OSUCCC) has five highly interactive cancer research programs. More than 300 scientists from 12 of the 15 colleges at The Ohio State University are members of one or more of these research programs. Most of the research in the Division of Surgical Oncology is translational, in which ideas and hypotheses from the laboratory are incorporated into clinical evaluation through the clinical trial mechanism.
Through the OSUCCC five programs, the work of members includes basic laboratory studies, translational research and clinical trials. While each program focuses on a different area of cancer research, the comprehensive cancer center promotes a strong culture of collaboration. Interprogrammatic collaborations, collaborations with researchers in these Ohio State colleges and collaborations with researchers at other cancer centers and institutions are encouraged. As a result, researchers can tackle complex and important questions that require broad, interdisciplinary expertise.
The research programs continue to grow in scientific and clinical strength through recruitment and retention of some of the world’s brightest minds in cancer research. The clear focus on collaborative and translational research and the availability of state-of-the-art technologies and expertise provided by 20 cores and shared resources, enables OSUCCC researchers to conduct high-quality research that leads to world-class discoveries, changes in clinical practice and improvements in patient care.
Surgical Oncology's Selected Research Grants
Carson III, William Edgar. Year 2 SWOG Network Group Operations Center of the NCTN. Oregon Health and Science University. $18,043. 03/01/15 – 02/29/16
Carson III, William Edgar. “Tumor Immunology.” Year 13 T32 Provides support to post-doctoral researchers performing translational research in immunology. NCI. $254,018. 08/01/2015-07/31/2016.
Farrar, William Blair. Breast and bowel treatment protocols agreement-SUBPART-B-50-I (KATHERINE) June 2013 Addendum. NSABP Fdn Inc. $56,065. 03/01/2013 - 02/28/2016
Farrar, William Blair. Breast and bowel treatment protocols agreement. NSABP Fdn Inc. $766,622. 02/01/1999 - 02/28/2016
Phay, John. Year 3: Core A: The Ohio State University and MD Anderson Cancer Center Thyroid Cancer SPORE (Phay). NCI. $258,500 08/01/2015 - 07/31/2016
Phay, John. Core A: Genetic and signaling pathways in epithelial thyroid cancer. NCI. $892,165. 04/30/2013 - 03/31/2016
Pollock, Raphael Etomar. Reactivating of apoptosis: A potential therapeutic target for desmoid tumors with CTNNB1 S45F mutation. Desmoid Tumor Research Foundation. $50,000. 12/01/2014 - 11/30/2015
Pollock, Raphael Etomar. Yr. 4 - SARC Sarcoma SPORE Core A. SARC.$19,905. 09/01/2015 - 08/31/2016
Pollock, Raphael Etomar. Yr. 4 - SARC Sarcoma SPORE Project 1. SARC. $19,025. 09/01/2015 - 08/31/2016
Learn more about our clinical research by cancer type:
- Breast Cancer
- Gastrointestinal Cancers
- Head and Neck Cancers
The OSUCCC – James has hundreds of open clinical trials at any given time, with some of the world’s latest discoveries available to clinical trial patients right here in Columbus, Ohio. In fact, patients have access to more cancer clinical trials here than at nearly any other hospital in the region, as well as access to some of the most advanced, targeted treatments and drugs available.
The OSUCCC – James is one of only a few U.S. cancer centers funded by the National Cancer Institute (NCI) to conduct phase I and phase II clinical trials on novel anti-cancer drugs. These trials go only to centers that demonstrate an exemplary capacity for research and clinical care, as well as the expertise to deliver the latest in treatments, and the infrastructure to interpret and track treatment results.